Platinum Resistant Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Platinum Resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer+4 more
Genelux Corporation186 enrolled31 locationsNCT05281471
Recruiting
Phase 1

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Endometrial CancerPlatinum Resistant Ovarian CancerPROC
Whitehawk Therapeutics, Inc.265 enrolled12 locationsNCT07470853
Recruiting
Phase 2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Endometrial CancerPlatinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+8 more
MacroGenics60 enrolled16 locationsNCT06730347
Recruiting
Phase 1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Ovarian CancerOvarian CarcinomaPlatinum Resistant Ovarian Cancer+4 more
Dana-Farber Cancer Institute18 enrolled2 locationsNCT06321484
Recruiting
Phase 1

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Ovarian CancerEndometrial CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc.226 enrolled12 locationsNCT07444814
Recruiting
Phase 1

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Endometrial CancerTesticular CancerPlatinum Resistant Ovarian Cancer
Context Therapeutics Inc.80 enrolled13 locationsNCT06515613
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1

A Study of MGC026 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerGastric Cancer+19 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Advanced High-Grade Epithelial OvarianPrimary PeritonealFallopian Tube Cancers+2 more
AbbVie110 enrolled37 locationsNCT06682988
Recruiting
Phase 1

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Ovarian CancerPlatinum Resistant Ovarian CancerOvarian Cancer Recurrent
Outpace Bio, Inc.30 enrolled4 locationsNCT07030907
Recruiting
Phase 1

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Platinum Resistant Ovarian Cancer
Stemline Therapeutics, Inc.100 enrolled1 locationNCT07226427
Recruiting
Phase 1Phase 2

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Platinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318
Recruiting
Phase 2

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Platinum Resistant Ovarian Cancer
ImmunityBio, Inc.20 enrolled2 locationsNCT06710288
Recruiting
Phase 2

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Platinum Resistant Ovarian CancerRefractory Ovarian Carcinoma
Cybrexa Therapeutics40 enrolled17 locationsNCT06315491
Recruiting
Phase 1

A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer

Advanced Ovarian CancerPlatinum Resistant Ovarian Cancer
Epsilogen Ltd45 enrolled7 locationsNCT06547840
Recruiting
Phase 1Phase 2

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum Resistant Ovarian Cancer
InxMed (Shanghai) Co., Ltd.150 enrolled7 locationsNCT05551507
Recruiting
Phase 2

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

Ovarian CancerPlatinum Resistant Ovarian Cancer
British Columbia Cancer Agency244 enrolled2 locationsNCT04787289